Novo Nordisk has purchased Berkeley Lights Beacon Optofluidic platform to accelerate workflows in cell line development and to use the platform for future protein and antibody discovery. The Beacon platform aims to reduce the extensive resources typically required to generate a cell line for commercial production by allowing for parallel screening, maintenance and analysis of thousands of cells. With the platform’s fully integrated and programmable workflow, the time expenditure for scr...